Related content

Cost-effective osteoporosis treatment thresholds: the United States perspective

By Tosteson A.   Melton L.   Dawson-Hughes B.   Baim S.   Favus M.   Khosla S.   Lindsay R.  

Osteoporosis International, Vol. 19, Iss. 4, 2008-04 ,pp. : 437-447

Springer Publishing Company

Access to resources Recommend Favorite

Hip fracture risk in older US adults by treatment eligibility status based on new National Osteoporosis Foundation guidance

By Looker A.   Dawson-Hughes B.   Tosteson A.   Johansson H.   Kanis J.   Melton L.  

Osteoporosis International, Vol. 22, Iss. 2, 2011-02 ,pp. : 541-549

Springer Publishing Company

Access to resources Recommend Favorite

Multifactorial evaluation and treatment of persons with a high risk of recurrent falling was not cost-effective

By Peeters G.   Heymans M.   Vries O.   Bouter L.   Lips P.   Tulder M.  

Osteoporosis International, Vol. 22, Iss. 7, 2011-07 ,pp. : 2187-2196

Springer Publishing Company

Access to resources Recommend Favorite

Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards

By Vasikaran S.   Eastell R.   Bruyère O.   Foldes A.   Garnero P.   Griesmacher A.   McClung M.   Morris H.   Silverman S.   Trenti T.   Wahl D.   Cooper C.   Kanis J.  

Osteoporosis International, Vol. 22, Iss. 2, 2011-02 ,pp. : 391-420

Springer Publishing Company

Access to resources Recommend Favorite

Effects of alendronate plus alfacalcidol in osteoporosis patients with a high risk of fracture: the Japanese Osteoporosis Intervention Trial (JOINT) –– 02

By Orimo Hajime   Nakamura Toshitaka   Fukunaga Masao   Ohta Hiroaki   Hosoi Takayuki   Uemura Yukari   Kuroda Tatsuhiko   Miyakawa Nobuaki   Ohashi Yasuo   Shiraki Masataka    

Current Medical Research and Opinion, Vol. 27, Iss. 6, 2011-06 ,pp. : 1273-1284

Informa Healthcare

Access to resources Recommend Favorite